PharmaCyte Biotech (PMCB) Stock Price, News & Analysis

Company Overview

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Key Stats

• Today's Range: $1.52 to $1.64
• 50-Day Range: $1.50 to $1.75
• 52-Week Range: $1.39 to $2.58
• Volume: 11,253 shs
• Average Volume: 12,468 shs
• Market Capitalization: $11.33 million
• P/E Ratio: 3.07
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PharmaCyte Biotech Stock Analysis - MarketRank™

PharmaCyte Biotech scored higher than 44% of companies evaluated by MarketBeat, and ranked 692nd out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for PharmaCyte Biotech.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of PharmaCyte Biotech is 3.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of PharmaCyte Biotech is 3.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.42.

Price to Book Value per Share Ratio

PharmaCyte Biotech has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.25% of the float of PharmaCyte Biotech has been sold short.

Short Interest Ratio / Days to Cover

PharmaCyte Biotech has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PharmaCyte Biotech has recently decreased by 48.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PharmaCyte Biotech does not currently pay a dividend.

Dividend Growth

PharmaCyte Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.25% of the float of PharmaCyte Biotech has been sold short.

Short Interest Ratio / Days to Cover

PharmaCyte Biotech has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PharmaCyte Biotech has recently decreased by 48.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.44

News Sentiment

PharmaCyte Biotech has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for PharmaCyte Biotech this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PharmaCyte Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.03% of the stock of PharmaCyte Biotech is held by insiders.

Percentage Held by Institutions

Only 34.24% of the stock of PharmaCyte Biotech is held by institutions.

PMCB Stock Analysis - Frequently Asked Questions

How have PMCB shares performed this year?

PharmaCyte Biotech's stock was trading at $1.57 at the beginning of 2025. Since then, PMCB shares have increased by 3.5% and is now trading at $1.6250.
View the best growth stocks for 2025 here.

How were PharmaCyte Biotech's earnings last quarter?

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) announced its earnings results on Friday, December, 13th. The company reported ($0.29) earnings per share for the quarter.

How do I buy shares of PharmaCyte Biotech?

Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PharmaCyte Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PharmaCyte Biotech investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), ASML (ASML), General Electric (GE), Oracle (ORCL) and Nokia Oyj (NOK).

Company Calendar

• Last Earnings: 12/13/2024
• Today: 2/01/2025
• Next Earnings (Estimated): 3/17/2025
• Fiscal Year End: 4/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PMCB
• CUSIP: N/A
• CIK: 1157075
• Web: pharmacyte.com
• Phone: 917-595-2850
• Fax: 917-595-2851
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.53
• Trailing P/E Ratio: 3.07
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $330,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 0.76%
• Return on Assets: 0.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.47
• Quick Ratio: 4.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.27 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 6,970,000
• Free Float: 6,896,000
• Market Cap: $11.33 million
• Optionable: Optionable
• Beta: -0.22